TY - JOUR
T1 - Whole-genome sequencing as a tool for studying the microevolution of drug-resistant serial Mycobacterium tuberculosis isolates
AU - de Lourdes do Carmo Guimarães Diniz, Jaciara
AU - von Groll, Andrea
AU - Unis, Gisela
AU - Dalla-Costa, Elis Regina
AU - Rosa Rossetti, Maria Lúcia
AU - Vianna, Júlia Silveira
AU - Ramos, Daniela Fernandes
AU - Reis, Ana Júlia
AU - Bartolomeu Halicki, Priscila Cristina
AU - Rheingantz Scaini, João Luis
AU - Castillos de Ibrahim das Neves, Yasmin
AU - Phelan, Jody
AU - Gomes, Ana Rita
AU - Campino, Susana
AU - Machado, Karina dos Santos
AU - Werhli, Adriano Velasque
AU - Pain, Arnab
AU - Clark, Taane Gregory
AU - Perdigão, João
AU - Viveiros, Miguel
AU - Portugal, Isabel
AU - Almeida Silva, Pedro Eduardo
N1 - Funding Information:
JLCGD was a Fellow of Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), PEAS is a Fellow of Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) productivity. The study had financial support by Project CNPq/Universal (401963/2016–0), CAPES (PVE- CAPES , 88881.064961/2014–01) and Fundação para a Ciência e Tecnologia ( FCT ), Portugal [UID/DTP/04138/2019]. This work was carried out with the support of the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil ( CAPES ) to working mission within the scope of the Capes-Print Program, Financing Code 001". JP was supported by FCT through Estímulo Individual ao Emprego Científico [CEECIND/00394/2017]. JEP is funded by a Newton Institutional Links Grant ( British Council , no. 261868591). TGC is funded by the Medical Research Council UK (Grant no. MR/M01360X/1, MR/N010469/1, MR/R025576/1, and MR/R020973/1) and BBSRC (Grant no. BB/R013063/1). SC is funded by Medical Research Council UK grants (ref. MR/M01360X/1, MR/R025576/1, and MR/R020973/1). AP is funded by a faculty baseline fund (BAS/1/1020-01-01) from KAUST .
Funding Information:
Special thanks to Dear Ruth McNerney for her support and help. We would also like to thank the Universidade Federal do Rio Grande, Faculdade de Farmácia of the Universidade de Lisboa , Instituto de Higiene e Medicina Tropical of the Universidade Nova de Lisboa , Conselho Nacional de Desenvolvimento Científico e Tecnológico ( CNPq ) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior ( CAPES ) for the structural support needed to realization this study.
Funding Information:
JLCGD was a Fellow of Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES), PEAS is a Fellow of Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq) productivity. The study had financial support by Project CNPq/Universal (401963/2016?0), CAPES (PVE-CAPES, 88881.064961/2014?01) and Funda??o para a Ci?ncia e Tecnologia (FCT), Portugal [UID/DTP/04138/2019]. This work was carried out with the support of the Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior - Brazil (CAPES) to working mission within the scope of the Capes-Print Program, Financing Code 001". JP was supported by FCT through Est?mulo Individual ao Emprego Cient?fico [CEECIND/00394/2017]. JEP is funded by a Newton Institutional Links Grant (British Council, no. 261868591). TGC is funded by the Medical Research Council UK (Grant no. MR/M01360X/1, MR/N010469/1, MR/R025576/1, and MR/R020973/1) and BBSRC (Grant no. BB/R013063/1). SC is funded by Medical Research Council UK grants (ref. MR/M01360X/1, MR/R025576/1, and MR/R020973/1). AP is funded by a faculty baseline fund (BAS/1/1020-01-01) from KAUST.Special thanks to Dear Ruth McNerney for her support and help. We would also like to thank the Universidade Federal do Rio Grande, Faculdade de Farm?cia of the Universidade de Lisboa, Instituto de Higiene e Medicina Tropical of the Universidade Nova de Lisboa, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq) and Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES) for the structural support needed to realization this study.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/12
Y1 - 2021/12
N2 - Treatment of drug-resistant tuberculosis requires extended use of more toxic and less effective drugs and may result in retreatment cases due to failure, abandonment or disease recurrence. It is therefore important to understand the evolutionary process of drug resistance in Mycobacterium tuberculosis. We here in describe the microevolution of drug resistance in serial isolates from six previously treated patients. Drug resistance was initially investigated through phenotypic methods, followed by genotypic approaches. The use of whole-genome sequencing allowed the identification of mutations in the katG, rpsL and rpoB genes associated with drug resistance, including the detection of rare mutations in katG and mixed populations of strains. Molecular docking simulation studies of the impact of observed mutations on isoniazid binding were also performed. Whole-genome sequencing detected 266 single nucleotide polymorphisms between two isolates obtained from one patient, suggesting a case of exogenous reinfection. In conclusion, sequencing technologies can detect rare mutations related to drug resistance, identify subpopulations of resistant strains, and identify diverse populations of strains due to exogenous reinfection, thus improving tuberculosis control by guiding early implementation of appropriate clinical and therapeutic interventions.
AB - Treatment of drug-resistant tuberculosis requires extended use of more toxic and less effective drugs and may result in retreatment cases due to failure, abandonment or disease recurrence. It is therefore important to understand the evolutionary process of drug resistance in Mycobacterium tuberculosis. We here in describe the microevolution of drug resistance in serial isolates from six previously treated patients. Drug resistance was initially investigated through phenotypic methods, followed by genotypic approaches. The use of whole-genome sequencing allowed the identification of mutations in the katG, rpsL and rpoB genes associated with drug resistance, including the detection of rare mutations in katG and mixed populations of strains. Molecular docking simulation studies of the impact of observed mutations on isoniazid binding were also performed. Whole-genome sequencing detected 266 single nucleotide polymorphisms between two isolates obtained from one patient, suggesting a case of exogenous reinfection. In conclusion, sequencing technologies can detect rare mutations related to drug resistance, identify subpopulations of resistant strains, and identify diverse populations of strains due to exogenous reinfection, thus improving tuberculosis control by guiding early implementation of appropriate clinical and therapeutic interventions.
KW - Catalase assay
KW - Exogenous reinfection
KW - Microevolution
KW - Resistance
KW - Whole-genome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85117228734&partnerID=8YFLogxK
U2 - 10.1016/j.tube.2021.102137
DO - 10.1016/j.tube.2021.102137
M3 - Article
C2 - 34673379
AN - SCOPUS:85117228734
SN - 1472-9792
VL - 131
SP - 1
EP - 9
JO - Tuberculosis
JF - Tuberculosis
M1 - 102137
ER -